Zobrazeno 1 - 10
of 13
pro vyhledávání: '"David Feltquate"'
Autor:
Jeffrey Sosman, Elad Sharon, Theresa LaVallee, Hussein A Tawbi, Ryan J Sullivan, Harriet M Kluger, Naiyer A Rizvi, David Feltquate
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
The need for solid clinical definitions of resistance to programmed death 1 or its ligand (PD-(L)1) inhibitors for clinical trial design was identified as a priority by the Society for Immunotherapy of Cancer (SITC). Broad consensus efforts have prov
Externí odkaz:
https://doaj.org/article/b4ec42c072fc44199e543822100f2358
Autor:
Laura C Cappelli, Maria E Suarez-Almazor, Michelle Turner, Stephane Champiat, Caroline Robert, Julie R Brahmer, Jarushka Naidoo, Jeffrey Weber, Joanne Riemer, Elad Sharon, Michael B Atkins, M Catherine Pietanza, Karthik Suresh, Catherine Murphy, Javid Moslehi, David Feltquate, Lee M Krug
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy may vary substantially in their clinical presentation, including natural history, outcomes to treatment, and patterns. The application of clinical guideli
Externí odkaz:
https://doaj.org/article/ce3651e8e8104a2ca8905bdbc8dd0dd4
Autor:
James L Gulley, Harriet Kluger, Hussein Tawbi, Jeffrey Sosman, Paolo A Ascierto, Michael B Atkins, Nikhil I Khushalani, Douglas B Johnson, Timonthy A Yap, Ryan J Sullivan, David Feltquate
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Immunotherapy offers deep and durable disease control to some patients, but many tumors do not respond to treatment with single-agent immune checkpoint inhibitors (ICIs). One strategy to enhance responses to immunotherapy is via combinations with sig
Externí odkaz:
https://doaj.org/article/2fe026f8decc4254bd877fb5ec451060
Autor:
Manish Sharma, Deanne Lathers, Melissa Johnson, Jason Luke, Igor Puzanov, Brendan Curti, Christopher Chen, Anthony El-Khoueiry, Brian Henick, Margaret Callahan, Mario Sznol, Sandip Patel, Dawn Wilson, Melissa Ricker, Lizhi Cao, Pushpa Jayaraman, Jenny Che, Li Peng, David Feltquate, Anthony Tolcher
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Jason J. Luke, Melissa Johnson, Anthony Tolcher, Christopher T. Chen, Tong Dai, Brendan D. Curti, Anthony El-Khoueiry, Mario Sznol, Brian S. Henick, Christine Horak, Pushpa Jayaraman, Christopher B. Cole, Dawn Wilson, Lizhi Cao, Li Peng, David Feltquate, Deanne Lathers, Manish R. Sharma
Publikováno v:
Cancer Research. 83:CT034-CT034
Background: Hypersialylation (excessive sialoglycans) on tumor cells has been known to be associated with poorer cancer outcomes for more than 40 years. Sialoglycans are immune suppressive and promote tumor immune evasion by binding to sialoglycan re
Autor:
Jarushka Naidoo, Catherine Murphy, Michael B Atkins, Julie R Brahmer, Stephane Champiat, David Feltquate, Lee M Krug, Javid Moslehi, M Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, Maria E Suarez-Almazor, Karthik Suresh, Michelle Turner, Jeffrey Weber, Laura C Cappelli
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006398
Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy may vary substantially in their clinical presentation, including natural history, outcomes to treatment, and patterns. The application of clinical guideli
Autor:
Michael B Atkins, Paolo A Ascierto, David Feltquate, James L Gulley, Douglas B Johnson, Nikhil I Khushalani, Jeffrey Sosman, Timonthy A Yap, Harriet Kluger, Ryan J Sullivan, Hussein Tawbi
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e005923
Immunotherapy offers deep and durable disease control to some patients, but many tumors do not respond to treatment with single-agent immune checkpoint inhibitors (ICIs). One strategy to enhance responses to immunotherapy is via combinations with sig
Autor:
Elad Sharon, Edward Cha, Maria Libera Ascierto, Charles G. Drake, Michael A. Postow, James L. Gulley, Dung T. Le, Eric H. Rubin, Margaret K. Callahan, Ryan J. Sullivan, Vassiliki A. Papadimitrakopoulou, Harriet M. Kluger, Hussein Abdul-Hassan Tawbi, Michaela Bowden, Shilpa Gupta, David Feltquate, R. Humphrey, Janis M. Taube, Theresa LaVallee, Helen X. Chen, Vanessa M. Hubbard-Lucey, Roberta Zappasodi, Suzanne L. Topalian, Mario Sznol, Robert L. Ferris
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously receiv
Autor:
Tatiana M. Prowell, Eric H. Rubin, Steven A. Reeves, S. Percy Ivy, Lillian L. Siu, David S. Hong, William Grossman, Nolan A. Wages, Elizabeth Garrett-Mayer, Gary L. Rosner, Timothy A. Yap, Jane Perlmutter, Gregory R. Pond, Brian P. Hobbs, David Feltquate, Yada Kanjanapan, Channing J. Paller, Lesley Seymour, Pedro C. Barata
Publikováno v:
JNCI Journal of the National Cancer Institute
Traditionally, drug development has evaluated dose, safety, activity, and comparative benefit in a sequence of phases using trial designs and endpoints specifically devised for each phase. Innovations in drug development seek to consolidate the phase
Publikováno v:
Pharmacology & Therapeutics. 148:132-153
The discovery and increased understanding of the complex interactions regulating the immune system have contributed to the pharmacologic activation of antitumor immunity. The activity of effector cells, such as T and NK cells, is regulated by an arra